CHEMOTHERAPY INDUCED THROMBOCYTOPENIA THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In: 25 Mar, 2025
Code: CMI4332
Pages: 156
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

Thrombocytopenia is a condition in which blood platelets are low in person’s body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.

Market Dynamics

The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.

However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Key features of the study:

This report provides in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market size (US$ 1,866.4 Mn) by 2027, and compound annual growth rate (CAGR) 5.0% for the forecast period: 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Amgen, Inc., Novartis AG., Pfizer Inc., LLC, Swedish Orphan Biovitrum AB., Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for dialysis market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
  - Others
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration:
- Oral
- Injectable
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel:
- Hospital Pharmaciesa
- Retail Pharmacies
- Online Pharmacies
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region:
- North America
  - By Country:
    - U.S.
    - Canada
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Europe
  - By Country:
    - U.K.
    - Germany
    - Italy
    - Spain
    - France
    - Russia
    - Rest of Europe
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Asia Pacific
  - By Country:
    - Australia
    - India
    - China
    - Japan
    - ASEAN
    - South Korea
    - Rest of Asia Pacific
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Latin America
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Middle East
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Africa
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
Company Profiles

Amgen, Inc.*

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Novartis AG
Pfizer Inc.
Swedish Orphan Biovitrum AB
Jiangsu HengRui Medicine Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.

“*” marked represents similar segmentation in other categories in the respective section.

Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - U.S.
    - Canada
- Europe
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Latin America
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Drug Class:
    - Thrombopoietin Receptor Agonists
    - Thrombopoietic Agents
    - Others
  - By Route of Administration:
    - Oral
    - Injectable
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region:
    - North Africa
    - Central Africa
    - South Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

CHEMOTHERAPY INDUCED THROMBOCYTOPENIA THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

By Drug Class:

By Route of Administration:

By Distribution Channel:

By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :